SpectRx faces Nasdaq downgrade/delisting
This article was originally published in Clinica
Diabetes and POC diagnostics producer SpectRx is facing the threat of Nasdaq delisting as the ongoing depression in emerging life science share prices causes many smaller companies to fall below the listing requirements.
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.